XmAb942

Xencor, Inc. · Phase 1 active Biologic

At a glance

Generic name	XmAb942
Sponsor	Xencor, Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

XmAb942 CI brief — competitive landscape report
XmAb942 updates RSS · CI watch RSS
Xencor, Inc. portfolio CI